Skip to main content

Fiscal Wizard · Single-issue tearsheet

ILMN / Jun 22, 2026 Run #7635

ILMN

Illumina, Inc.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Composite verdict

A 83.5 / 100
Bullish setup · Trend Following 13 drivers · 2 gates blocking
  • Double 7s
  • Trendline Break
  • ADX DI Cross
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 1st of 48 in Diagnostics & Research

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 20 signals0% Bear
Momentum Bullish 88Mean-reversion Bullish 60
  • Pullback buyOversold in an uptrend — a pullback buy: mean-reversion aligned with the primary trend, the high-value case for an oversold signal. (medium confidence)
Where value comes fromMargin of safety -84%
Asset value $18.00Earnings power value $51.31Price $161.93

Priced above its no-growth earnings power value ($51.31/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

67.1 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Cash Conversion 84
Revenue Growth (YoY) 0
Return on Capital Employed 82
Cash Conversion Cycle 0

Technicals Bullish

99.9 / 100

Bullish setup leads (Double 7s, Trendline Break, Williams %R); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Trendline Break 88
Double 7s 88
ADX DI Cross 77

Risk Gates

2 blocking 3 caution

2 guards active, 19 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

ADX Trend Weakness Weak-trend caution

Weak trend strength blocks trend-following signals in either direction.

Earnings Event Blackout Caution

Mutes all technical signals within the earnings announcement window when earnings dates are available.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ILMN.